$FIXX News

Last published 2y ago

2y agoFIXXHomology Medicines Declares Distribution to Common StockholdersGlobeNewswireBEDFORD, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX) today announced that it declared a distribution to its common stockholders of record as of the close of business on March 21,
2y agoEVRI FIXX GRPH SCTLKuehn Law Encourages FIXX, SCTL, EVRI, and GRPH Investors to Contact Law FirmGlobeNewswireNEW YORK, March 01, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures
2y agoFIXXHomology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price DeficiencyGlobeNewswireHomology Medicines has an initial 180-day period through June 26, 2024 to regain compliance with Minimum Bid Price Requirement BEDFORD, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX)
2y agoFIXXQ32 Bio and Homology Medicines Announce Merger AgreementPR NewswireQ32 Bio Inc., a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Homology Medicines, Inc....
2y agoFIXXQ32 Bio and Homology Medicines Announce Merger AgreementGlobeNewswire--The combined company will operate as Q32 Bio Inc., advancing the development of Q32 Bio's two clinical development candidates, bempikibart (ADX-914) in Phase 2 for the treatment of atopic dermatitis (AD) and alopecia
2y agoFIXXHomology Medicines Reports Third Quarter 2023 Financial ResultsGlobeNewswire- Continuing to Evaluate Strategic Options for the Company and the Pipeline of Genetic Medicines, including HMI-103 - BEDFORD, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a genetic
3y agoFIXXHomology Medicines Reports Second Quarter 2023 Financial Results and Recent HighlightsGlobeNewswire- Reported Encouraging Initial Data from First Cohort of Phase 1 Trial Evaluating Gene Editing Candidate HMI-103 in Adults with PKU - - Evaluating Strategic Options for the Company and Pipeline of Genetic Medicines,
3y agoFIXXHomology Medicines Announces Plan to Evaluate Strategic Options for the Company and its Genetic Medicines Programs, including HMI-103 Gene Editing Candidate for PKUGlobeNewswireAnnounced Today Encouraging Initial Clinical Data from First Dose Level of pheEDIT Trial Evaluating HMI-103 BEDFORD, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a genetic medicines
3y agoFIXXHomology Medicines Announces Encouraging Initial Data from First Dose Level in the pheEDIT Trial Evaluating Gene Editing Candidate HMI-103 in Adults with Classical PKUGlobeNewswireParticipant 1 Achieved Clinically Meaningful Reduction in Plasma Phe of Up to 99% Change from Baseline and Below the U.S. PKU Treatment Guideline Threshold (<360 μmol/L)*; At 31 Weeks Post-Dose, Phe Level 319
3y agoFIXXHomology Medicines Announces First Data from IND-Enabling Studies with GTx-mAb Candidate HMI-104 for PNH, Which Demonstrated Sustained Expression of Functional C5mAb Levels, at the ASGCT Annual MeetingGlobeNewswire- New Preclinical Data Demonstrated Ability to Re-Dose with AAVHSCs Across Viral Clades, Potentially Expanding Possibilities of Genetic Medicine Programs in the Future - - Presented Methods to Accelerate Identification
3y agoFIXXHomology Medicines Reports First Quarter 2023 Financial Results and Recent HighlightsGlobeNewswire- On Track to Report Initial Clinical Data from pheEDIT PKU Gene Editing Trial Mid-Year 2023 - - First Presentations of Preclinical Data with GTx-mAb Development Candidate HMI-104 for PNH, and Potential for Re-Dosing
3y agoFIXXHomology Medicines Announces Upcoming Presentations Highlighting its Genetic Medicines Platform, including New Data from IND-Enabling Studies with GTx-mAb Development Candidate HMI-104 for PNH, at ASGCT Annual MeetingGlobeNewswire- First Preclinical Data Sets Demonstrating Potential to Re-Dose with AAVHSCs and to Identify Genomic Sites with Improved Gene Editing Integration Efficiency - BEDFORD, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Homology
3y agoFIXXHomology Medicines Announces Presentations on Design of Ongoing Gene Editing and Gene Therapy Trials for PKU and Hunter Syndrome at ACMG Annual Clinical Genetics MeetingGlobeNewswireBEDFORD, Mass., March 15, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a genetic medicines company, announced two presentations during the ACMG Annual Clinical Genetics Meeting, which highlight the
3y agoFIXXHomology Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Recent HighlightsGlobeNewswire- On Track to Provide Initial Clinical Data from Gene Editing Trial for PKU Mid-Year with First Participant Dosed and Others in Screening - - Initial Clinical Data from Gene Therapy Trial for Hunter Syndrome
3y agoFIXXHomology Medicines Announces Promotion of Julie Jordan, M.D., to Chief Medical OfficerGlobeNewswireBEDFORD, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a genetic medicines company, announced today that Julie Jordan, M.D., has been promoted to Chief Medical Officer. Previously,
3y agoFIXXHomology Medicines to Participate in the 43rd Annual Cowen Healthcare ConferenceGlobeNewswireBEDFORD, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a genetic medicines company, announced today that Albert Seymour, Ph.D., President and Chief Executive Officer, will
3y agoFIXXHomology Medicines Presents Preclinical Data Supporting Immunosuppression Regimen in Ongoing PKU and Hunter Syndrome Clinical Trials, and Details Optimized MLD Gene Therapy Candidate at the 19th Annual WORLDSymposium™ MeetingGlobeNewswirePreclinical Studies Demonstrated a Targeted Immunosuppression Approach Led to Reduced Immune Response to AAVHSC Administration and Improved Gene Expression In Vivo Gene Therapy Candidate HMI-204 for MLD Showed Robust
3y agoFIXXHomology Medicines Provides Update on pheEDIT and juMPStart Clinical Trials and Announces Expected 2023 Milestones, Including Initial Data Read-Outs from Both ProgramsGlobeNewswireStrong Cash Position with Runway into Fourth Quarter 2024 Non-Clinical Data on Immunosuppression Regimen Supportive of Clinical Programs Preclinical Data from HMI-103 Gene Editing Program Utilizing a Unique Mechanism
4y agoFIXXHomology Medicines Reports Third Quarter 2022 Financial Results and Recent HighlightsGlobeNewswire- On Track for Updates on pheEDIT and juMPStart Programs by Year-End - - Strong Financial Position with Cash Runway into Fourth Quarter 2024 - - Promoted Albert Seymour, Ph.D., to Chief Executive Officer Driving
4y agoFIXXHomology Medicines Presents on Design of pheEDIT Trial Evaluating One-Time Nuclease-Free Gene Editing Candidate HMI-103 for PKU at American Society of Human Genetics MeetingGlobeNewswire- Additional Presentation Focused on Use of Single-Molecule, Modified Base Sequencing to Support Vector Design - BEDFORD, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a genetic
4y agoAKUS CINC FIXX IONS+1Arthur Tzianabos, Ph.D., June Lee, MD FACCP, and Joseph Loscalzo, MD, Ph.D. Join 5AM VenturesGlobeNewswireSAN FRANCISCO and BOSTON, Sept. 27, 2022 (GLOBE NEWSWIRE) -- 5AM Ventures, a bicoastal venture capital firm, continues to attract preeminent talent as it celebrates 20 years of investing in early-stage life science companies. The firm is currently depl
4y agoFIXXHomology Medicines Appoints Albert Seymour, Ph.D., Chief Executive OfficerGlobeNewswireArthur Tzianabos, Ph.D., Named Chairperson of the Board of Directors BEDFORD, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a genetic medicines company, announced today the promotion of Albert Seymour, Ph.D., to
4y agoFIXXHomology Medicines Reports Second Quarter 2022 Financial Results, Recent Highlights and Provides Business UpdateGlobeNewswire- On Track for Updates on pheEDIT and juMPStart Programs by End of 2022 - - Prioritized Pipeline, Shifting Resources to HMI-103 PKU Gene Editing Trial in Adults While Pausing Enrollment in HMI-102 PKU Gene Therapy Trial Also in Adults - - Received
4y agoFIXXHomology Medicines Announces Optimized, In Vivo Gene Therapy Candidate for the Treatment of Metachromatic LeukodystrophyGlobeNewswire- Candidate Showed Ability to Target Central Nervous System and Peripheral Organs Following a Single I.V. Administration in MLD Model, a Key Differentiator from Available Treatments and Product Candidates - - Data Demonstrated Biodistr
4y agoFIXXHomology Medicines Announces Peer-Reviewed Publication on Novel Discovery of AAVHSC with Robust Distribution to the Central Nervous System and Peripheral Organs with Low Affinity for the LiverGlobeNewswireAAVHSC16 Biodistribution Properties in Preclinical Models Demonstrated Potential for Systemic Delivery of Genetic Medicines to Brain, Heart and Muscle BEDFORD, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a genet
4y agoFIXXHomology Medicines to Present at Upcoming Conferences on its Gene Editing and Gene Therapy Programs for PKUGlobeNewswireBEDFORD, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a genetic medicines company, announced today participation and presentations at the following conferences: FASEB's The Genome Engineering Conference: Cutting-E
4y agoFIXXHomology Medicines Announces FDA Lifted Clinical Hold on pheNIX Gene Therapy Trial for PKUGlobeNewswire- Company Increased Risk-Mitigation Strategies, Including a Steroid-SparingImmunosuppression Regimen - BEDFORD, Mass., June 13, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a genetic medicines company, announced today that the U.
4y agoFIXXHomology Medicines Presents Details of Optimized HMI-103 Nuclease-Free Gene Editing Candidate Featuring Integrated Liver-Specific Promoter to Maximize Long-Term ExpressionGlobeNewswire- Additional Data at ASGCT Annual Meeting Demonstrate Precision of HR-Based Approach with Genome-Wide Integration Assays Confirming On-Target Editing and No Off-Target Events - - New Data from GTx-mAb Platform Support Potential for Targeting Many Comp
4y agoFIXXHomology Medicines Reports First Quarter 2022 Financial Results and Recent HighlightsGlobeNewswire- $130 Million in Non-Dilutive Capital Strengthened Financial Position - - Presentations at Upcoming ASGCT Annual Meeting Include First-Time Details of Mechanism of Action of Nuclease-Free Gene Editing Candidate HMI-103 for PKU; Symposium to Feature L
4y agoFIXXHomology Medicines Announces Upcoming Presentation on Optimized In Vivo Gene Editing Candidate HMI-103 with First Details of Unique Mechanism of Action at ASGCT Annual MeetingGlobeNewswire- Multiple Presentations Feature HMI-103 Phase 1 Investigational Therapy for PKU, Including Genome-Wide Integration Assays to Confirm No Off-Target Editing - - New Data from GTx-mAb Program Support Potential to Target Many Complement-Related Disorders
4y agoFIXXHomology Medicines Announces Promotion of Albert Seymour, Ph.D., to PresidentGlobeNewswireBEDFORD, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a genetic medicines company, announced today that Albert Seymour, Ph.D., Chief Scientific Officer, has been promoted to President of Homology. In addition to his
4y agoFIXXFIXX Stock News: Robbins LLP Investigates Homology Medicines, Inc. (FIXX) for ShareholdersBusiness WireShareholder rights law firm Robbins LLP is investigating Homology Sciences, Inc. (NASDAQ:FIXX) and its officers and directors to determine whether they breached their fiduciary duties and violated securities laws in relation to the misstatements concern
4y agoFIXXHomology Medicines Reports Fourth Quarter and Full Year 2021 Financial Results and Recent HighlightsGlobeNewswire- Formed New AAV Manufacturing and Innovation Business with Oxford Biomedica to Leverage Homology's Process Development and Manufacturing Capabilities - - Received $130 Million Non-Dilutive Capital that Significantly Extends Cash Runway - - Launche
4y agoFIXXOxford Biomedica broadens its viral vector capabilities with the launch of Oxford Biomedica Solutions, a full scope AAV business in Boston, following closing of its deal with HomologyGlobeNewswireUnique platform offering capabilities from vector design and process development through to clinical trials is now available to new customers Oxford, UK – 11 March 2022: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or the "Company"), a lea
4y agoFIXXHomology Medicines Announces Closing of Deal Leveraging its Internal Process Development and CMC Capabilities Through Newly Formed AAV Manufacturing Innovation Business with Oxford BiomedicaGlobeNewswireBEDFORD, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a genetic medicines company, announced today the successful closing of the deal with Oxford Biomedica plc (LSE: OXB) to establish an Adeno-Associated Virus (AAV)
4y agoFIXXHomology Medicines to Participate in Upcoming Investor ConferencesGlobeNewswireBEDFORD, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a genetic medicines company, announced today participation at the following virtual investor conferences: Cowen 42nd Annual Health Care Conference: Corpora
4y agoFIXXHomology Medicines Provides an Update on pheNIX Gene Therapy Trial for Adults with PKUGlobeNewswireBEDFORD, Mass., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a genetic medicines company, announced today that the U.S. Food and Drug Administration (FDA) has notified the company that its pheNIX gene therapy trial of HMI-1
4y agoFIXXSafety and Efficacy of HMI-203 in ERT-Treated Adults With MPS II - NCT05238324ClinicalTrials.govEvaluate the incidence and severity of adverse events of special interest (AESIs) and serious adverse events (SAEs) of a single dose administration of HMI-203 (at each dose level) in adult participants with MPS II, Assess long-term safety of HMI-203 in single administration in adult participants with MPS II by monitoring changes in 12-lead electrocardiograms (ECGs), Assess long-term safety of HMI- ...
4y agoFIXXHomology Medicines Announces Presentations on HMI-203 Investigational Gene Therapy for Hunter Syndrome and Broad Applicability of AAVHSC Platform for Lysosomal Storage Disorders at the 18th Annual WORLDSymposium™ MeetingGlobeNewswire- Data Supported juMPStart Trial Evaluating One-Time, Systemic Administration of HMI-203 in ERT-Treated Adults - - Details of HMI-203 Clinical Trial Design and Encouraging Preclinical Data Featured in Platform Presentations - BEDFORD, Mass., Feb.
4y agoFIXXSafety and Efficacy of HMI-103, a Gene Editing Development Candidate in Adults With Classical PKU Due to PAH Deficiency - NCT05222178ClinicalTrials.govTo determine incidence and severity of Treatment Emergent Adverse Events and adverse events of special interest of a single administration of HMI-103, To evaluate the efficacy of HMI-103 on reduction of plasma Phe concentration at each dose level, To evaluate the effect of HMI-103 on plasma Phe concentration relative to treatment guidelines for PKU, (and 2 more...)
4y agoFIXXOxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines' established AAV capabilities into a newly formed AAV Manufacturing and Innovation Business in the U.S. with Homology Medicines as 20% ownerGlobeNewswireOxford Biomedica and Homology Medicines to establish Oxford Biomedica Solutions LLC, a new U.S.-based AAV Manufacturing and Innovation Business Homology Medicines to receive $130 million from Oxford Biomedica to continue to advance its three clinica
4y agoFIXXHomology Medicines Reports Third Quarter 2021 Financial Results and Recent HighlightsGlobeNewswire- Achieved Goal of Three Clinical Programs Across Gene Therapy and Gene Editing Technology Platform This Year - - Start of First Gene Editing Trial Advances Mission to Develop Solutions for Both Adults and Pediatric Patients with PKU - - Initiated
5y agoFIXX MRKMerck's Covid pill approved by UK regulator, a potential game-changer in fighting the pandemicCNBCAn antiviral pill found to be effective at treating Covid-19 has been approved by Britain's medicines regulator Thursday in a potentially game-changing way of treating the virus.
5y agoFIXXHomology Medicines to Participate in Upcoming Investor ConferencesGlobeNewswireBEDFORD, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a clinical-stage genetic medicines company, announced today participation in the following virtual conferences: Credit Suisse 30th Annual Healthcare Confere
5y agoFIXXHomology Medicines Announces Presentations Across Gene Therapy and Gene Editing Programs, including GTx-mAb, at European Society of Gene & Cell Therapy MeetingGlobeNewswire- Data Support PKU and Hunter Syndrome Clinical Trials and PNH Program - BEDFORD, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a genetic medicines company, announced today four presentations of preclinical data
5y agoFIXXHomology Medicines Announces Presentation of Data Supporting Clinical Programs in MPS II and PKU, including Nonclinical and Patient-Focused Research, at American Society of Human Genetics MeetingGlobeNewswire- Oral Presentation on In Vivo Gene Therapy Product Candidate and Data on Gene Editing Candidate Paved Way for Initiation of juMPStart and pheEDIT Trials - BEDFORD, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a g
5y agoFIXXHomology Medicines Initiates Clinical Trial for HMI-203, a One-Time Investigational Gene Therapy Candidate for Adults with MPS II (Hunter Syndrome)GlobeNewswire- juMPStart Trial to Evaluate First Systemic Gene Therapy Candidate for Patients with Hunter Syndrome - BEDFORD, Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a genetic medicines company, announced today that it ha
5y agoFIXXHomology Medicines Announces World's First Gene Editing Clinical Trial for PKUGlobeNewswire- IND Clearance of pheEDIT Study to Evaluate a One-Time Dose of Investigational HMI-103 Incorporating a Novel Nuclease-Free Gene Editing Approach - - Company Provides Update on Enrollment in Ongoing pheNIX Trial of HMI-102 Gene Therapy for Adults w
5y agoFIXXHomology Medicines Reports Second Quarter 2021 Financial Results and Recent HighlightsGlobeNewswire- On Track to Report Initial Results from Phase 2 pheNIX Gene Therapy Trial for Adults with PKU in 2021- - Plans to Initiate First-Ever Gene Editing Trial for PKU with HMI-103 This Year - - Expects to Commence Clinical Trial with HMI-203 In Vivo Ge
5y agoFIXXHomology Medicines Appoints Gene Therapy Pioneer Beverly Davidson, Ph.D., as Chair of Scientific Advisory BoardGlobeNewswire- ASGCT President and Entrepreneur Takes Leadership Role on SAB as Company Expects to Have Three Clinical Programs in 2021 - BEDFORD, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a clinical-stage genetic medicin